Approval · Notice of Compliance 34039 · 2024

AYVAKYT: Notice of Compliance 34039

Issued September 18, 2024

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 34039
Date: September 18, 2024
Company: Blueprint Medicines CorporationCambridge, Massachusetts, United States
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: New Active Substance (NAS)

Products in this notice

Brand	DIN	Status today
AYVAKYT	02551764	Marketed
AYVAKYT	02551772	Marketed
AYVAKYT	02551780	Marketed
AYVAKYT	02551799	Marketed

Medicinal ingredients

AVAPRITINIB 25 MG per TAB
AVAPRITINIB 50 MG per TAB
AVAPRITINIB 100 MG per TAB
AVAPRITINIB 200 MG per TAB